Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 4
2006 4
2008 1
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Preoperative Chemoradiotherapy for Resectable Gastric Cancer.
Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. Leong T, et al. N Engl J Med. 2024 Nov 14;391(19):1810-1821. doi: 10.1056/NEJMoa2405195. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282905 Clinical Trial.
A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06.
Burmeister BH, Mark Smithers B, Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C, Spry N; Trans Tasman Radiation Oncology Group. Burmeister BH, et al. Radiother Oncol. 2006 Nov;81(2):136-42. doi: 10.1016/j.radonc.2006.10.001. Epub 2006 Oct 24. Radiother Oncol. 2006. PMID: 17064803 Clinical Trial.
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, Berry MP, Keller J, Tripcony L; Trans Tasman Radiation Oncology Group. Gogna NK, et al. Radiother Oncol. 2006 Oct;81(1):9-17. doi: 10.1016/j.radonc.2006.09.001. Epub 2006 Sep 28. Radiother Oncol. 2006. PMID: 17011058 Clinical Trial.
Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
O'Brien PC, Roos DE, Pratt G, Liew KH, Barton MB, Poulsen MG, Olver IN, Trotter GE; Trans-Tasman Radiation Oncology Group. O'Brien PC, et al. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):408-13. doi: 10.1016/j.ijrobp.2005.07.958. Epub 2005 Sep 28. Int J Radiat Oncol Biol Phys. 2006. PMID: 16198065 Clinical Trial.
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group. Denham JW, et al. Lancet Oncol. 2005 Nov;6(11):841-50. doi: 10.1016/S1470-2045(05)70348-X. Lancet Oncol. 2005. PMID: 16257791 Clinical Trial.
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).
Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, Hoskin PJ, Ball DL; Trans-Tasman Radiation Oncology Group, TROG 96.05. Roos DE, et al. Radiother Oncol. 2005 Apr;75(1):54-63. doi: 10.1016/j.radonc.2004.09.017. Epub 2004 Oct 28. Radiother Oncol. 2005. PMID: 15878101 Clinical Trial.
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ; Trans-Tasman Radiation Oncology Group Study 98.02. Rischin D, et al. J Clin Oncol. 2006 May 1;24(13):2098-104. doi: 10.1200/JCO.2005.05.2878. J Clin Oncol. 2006. PMID: 16648512 Clinical Trial.
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C; Trans-Tasman Radiation Oncology Group 96.01 Trialists. Denham JW, et al. Lancet Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5. Epub 2008 Oct 15. Lancet Oncol. 2008. PMID: 18929505
Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials.
Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ; Trans-Tasman Radiation Oncology Group and the De-ESCALaTE HPV Trial Group. Rischin D, et al. Ann Oncol. 2022 Aug;33(8):804-813. doi: 10.1016/j.annonc.2022.04.074. Epub 2022 May 4. Ann Oncol. 2022. PMID: 35525376 Free article.
11 results